Brooks Lab.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE650L01011
NSEID: BROOKS
BSEID: 533543

INR

99.45

-0.25 (-0.25%)

BSENSE

Dec 05

BSE+NSE Vol: 29.28 k

{
  "main_header": {
    "sid": 539063,
    "name": "Brooks Lab.",
    "stock_name": "Brooks Lab.",
    "full_name": "Brooks Laboratories Ltd",
    "name_url": "stocks-analysis/brooks-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "99.45",
    "chg": -0.25,
    "chgp": "-0.25%",
    "dir": -1,
    "prev_price": "99.70",
    "mcapval": "292.95 Cr",
    "mcap": "Micro Cap",
    "scripcode": 533543,
    "symbol": "BROOKS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE650L01011",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "29.28 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/brooks-lab-539063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Brooks Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-brooks-lab-fallingrising-3747218",
        "imagepath": "",
        "date": "2025-12-05 00:50:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Trend Reversal</strong></p>\n<p>Brooks Laboratories’ share price rose by ₹0.9, or 0.9%, as of 08:26 PM on 04-Dec, following five consecutive days of declines. This gain represents a tentative trend reversal, signalling some renewed investor interest. However, the stock remains approximately 4.76% above its 52-week low of ₹95.95, indicating it is still trading near the bottom of its recent range. The recovery today also outperformed the broader sector by 0.61%, suggesting relative strength in the short term.</p>\n<p><strong>Long-Term Underperformance Against Benchmarks</strong></p>\n<p>Despite the recent bounce, Brooks Laboratories has underperformed significantly over multiple time horizons when compared to the Sensex. Over the past week, the stock declined by 4.14%, w..."
      },
      {
        "title": "Brooks Lab. Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brooks-lab-downgraded-to-strong-sell-by-marketsmojo-amid-deteriorating-fundamentals-3741047",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLab_mojoScore_3741047.png",
        "date": "2025-12-02 10:09:46",
        "description": "Brooks Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial and technical factors. The recent assessment highlights challenges in valuation and technical outlook, despite some positive financial trends, underscoring the nuanced position of the company within its sector."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.97.6",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-falls-to-52-week-low-of-rs976-3725551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrooksLaborator_priceRelatedfactors_3725551.png",
        "date": "2025-11-24 13:19:48",
        "description": "Brooks Laboratories has reached a new 52-week low of Rs.97.6, marking a significant decline in its stock price amid broader market gains. The pharmaceutical and biotechnology company’s shares have experienced a notable downturn over recent sessions, reflecting ongoing challenges in its financial performance and valuation metrics."
      },
      {
        "title": "Brooks Laboratories Q2 FY26: Sharp Profit Decline Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/brooks-laboratories-q2-fy26-sharp-profit-decline-amid-margin-pressures-3719317",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrooksLaborator_quaterlyResult_3719317.png",
        "date": "2025-11-18 15:17:04",
        "description": "Brooks Laboratories Limited, a Baddi-based contract pharmaceutical manufacturer, reported a challenging second quarter for FY2026, with consolidated net profit plunging 16.70% quarter-on-quarter to ₹7.98 crores despite maintaining year-on-year growth momentum. The micro-cap pharmaceutical company, with a market capitalisation of ₹304.00 crores, saw its stock trading at ₹103.70 on November 18, down 48.87% from its 52-week high of ₹202.80, reflecting investor concerns over deteriorating operational metrics and sustained margin pressures."
      },
      {
        "title": "How has been the historical performance of Brooks Lab.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-brooks-lab-3702972",
        "imagepath": "",
        "date": "2025-11-14 23:40:30",
        "description": "Answer:\nThe historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.\n\nBreakdown:\nBrooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar..."
      },
      {
        "title": "Why is Brooks Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-brooks-lab-fallingrising-3653526",
        "imagepath": "",
        "date": "2025-10-29 00:04:12",
        "description": "As of 28-Oct, Brooks Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 106.70, which represents a decrease of Rs 6.15 or 5.45%. The stock has been underperforming significantly, having fallen for three consecutive days, resulting in a total drop of 12.51% during this period. Additionally, the stock's performance over the past week and month shows a decline of 11.96% and 22.00%, respectively, while year-to-date returns are down by 42.31%. The stock is trading below all key moving averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 115.24% against the five-day average, the overall sentiment remains negative, contributing to the stock's downward movement.\n\nIn the broader market context, Brooks Laboratories Ltd's performance contrasts sharply with the Sensex, which has shown a slight increase of 0.24% over the past week ..."
      },
      {
        "title": "How has been the historical performance of Brooks Lab.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-brooks-lab-3652786",
        "imagepath": "",
        "date": "2025-10-28 22:44:31",
        "description": "Answer:\nThe historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.\n\nBreakdown:\nBrooks Lab's net sales increased from 63.20 Cr in March 2023 to 82.56 Cr in March 2025, reflecting a recovery from a dip in March 2022 when sales were at 91.08 Cr. The total operating income followed a similar pattern, rising to 82.56 Cr in March 2025 from a low of 63.20 Cr in March 2023. However, the company faced challenges with operating profit, which was negative in March 2023 at -26.42 Cr, but improved to 4.94 Cr by March 2025. Despite this improvement, the consolidated net profit remained negative, at -9.97 Cr in March 2025, although it was an improvement from -19.59 Cr in March 2024. The company's total liabilities increased to 123.69 Cr in March 2025 from 90.45 Cr in March 2024, while total assets also rose to 123.69 Cr in March 2025. Cash flow from operating acti..."
      },
      {
        "title": "Brooks Laboratories Faces Bearish Outlook Despite Positive Financial Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brooks-laboratories-stock-downgraded-to-strong-sell-amid-bearish-trends-3650172",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BrooksLaborator_mojoScore_3650172.png",
        "date": "2025-10-28 08:11:12",
        "description": "Brooks Laboratories, a microcap in the Pharmaceuticals & Biotechnology sector, has undergone a recent evaluation adjustment reflecting a bearish technical outlook. Despite strong Q1 FY25-26 financial results, long-term fundamentals reveal challenges, including a stagnant growth rate and difficulties in debt servicing, contributing to a negative annual return."
      },
      {
        "title": "Brooks Laboratories Forms Death Cross, Signaling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-forms-death-cross-signaling-potential-bearish-trend-3648941",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/BrooksLaborator_dealthcross_3648941.png",
        "date": "2025-10-27 18:25:37",
        "description": "Brooks Laboratories has recently encountered a Death Cross, indicating a potential shift in market sentiment. The stock has declined 1.54% today and has underperformed over the past year, with a significant drop compared to the Sensex. Technical indicators suggest ongoing challenges for the company."
      }
    ],
    "total": 242,
    "sid": "539063",
    "stock_news_url": "https://www.marketsmojo.com/news/brooks-laboratories-539063"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "Newspaper Publication dated 15th November 2025 of the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 14Th November 2025.",
      "datetime": "14-Nov-2025",
      "details": "Outcome of the Board Meeting held on Friday 14th November 2025.",
      "source": "BSE"
    },
    {
      "caption": "Results For Quarter And Half Year Ended 30Th September 2025",
      "datetime": "14-Nov-2025",
      "details": "Approved Results for quarter and half year ended 30th September 2025 at Board Meeting held on Friday 14th November 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Brooks Laboratories Ltd has announced <strong>1:16</strong> rights issue, ex-date: 28 Jul 23",
          "dt": "2023-07-28",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Why is Brooks Lab. falling/rising?

2025-12-05 00:50:46

Recent Price Movement and Trend Reversal

Brooks Laboratories’ share price rose by ₹0.9, or 0.9%, as of 08:26 PM on 04-Dec, following five consecutive days of declines. This gain represents a tentative trend reversal, signalling some renewed investor interest. However, the stock remains approximately 4.76% above its 52-week low of ₹95.95, indicating it is still trading near the bottom of its recent range. The recovery today also outperformed the broader sector by 0.61%, suggesting relative strength in the short term.

Long-Term Underperformance Against Benchmarks

Despite the recent bounce, Brooks Laboratories has underperformed significantly over multiple time horizons when compared to the Sensex. Over the past week, the stock declined by 4.14%, w...

Brooks Lab. Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-02 10:09:46

Brooks Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial and technical factors. The recent assessment highlights challenges in valuation and technical outlook, despite some positive financial trends, underscoring the nuanced position of the company within its sector.

Brooks Laboratories Stock Falls to 52-Week Low of Rs.97.6

2025-11-24 13:19:48

Brooks Laboratories has reached a new 52-week low of Rs.97.6, marking a significant decline in its stock price amid broader market gains. The pharmaceutical and biotechnology company’s shares have experienced a notable downturn over recent sessions, reflecting ongoing challenges in its financial performance and valuation metrics.

Brooks Laboratories Q2 FY26: Sharp Profit Decline Amid Margin Pressures

2025-11-18 15:17:04

Brooks Laboratories Limited, a Baddi-based contract pharmaceutical manufacturer, reported a challenging second quarter for FY2026, with consolidated net profit plunging 16.70% quarter-on-quarter to ₹7.98 crores despite maintaining year-on-year growth momentum. The micro-cap pharmaceutical company, with a market capitalisation of ₹304.00 crores, saw its stock trading at ₹103.70 on November 18, down 48.87% from its 52-week high of ₹202.80, reflecting investor concerns over deteriorating operational metrics and sustained margin pressures.

How has been the historical performance of Brooks Lab.?

2025-11-14 23:40:30

Answer: The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years. Breakdown: Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar...

Why is Brooks Lab. falling/rising?

2025-10-29 00:04:12

As of 28-Oct, Brooks Laboratories Ltd is experiencing a decline in its stock price, currently at Rs 106.70, which represents a decrease of Rs 6.15 or 5.45%. The stock has been underperforming significantly, having fallen for three consecutive days, resulting in a total drop of 12.51% during this period. Additionally, the stock's performance over the past week and month shows a decline of 11.96% and 22.00%, respectively, while year-to-date returns are down by 42.31%. The stock is trading below all key moving averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 115.24% against the five-day average, the overall sentiment remains negative, contributing to the stock's downward movement. In the broader market context, Brooks Laboratories Ltd's performance contrasts sharply with the Sensex, which has shown a slight increase of 0.24% over the past week ...

How has been the historical performance of Brooks Lab.?

2025-10-28 22:44:31

Answer: The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years. Breakdown: Brooks Lab's net sales increased from 63.20 Cr in March 2023 to 82.56 Cr in March 2025, reflecting a recovery from a dip in March 2022 when sales were at 91.08 Cr. The total operating income followed a similar pattern, rising to 82.56 Cr in March 2025 from a low of 63.20 Cr in March 2023. However, the company faced challenges with operating profit, which was negative in March 2023 at -26.42 Cr, but improved to 4.94 Cr by March 2025. Despite this improvement, the consolidated net profit remained negative, at -9.97 Cr in March 2025, although it was an improvement from -19.59 Cr in March 2024. The company's total liabilities increased to 123.69 Cr in March 2025 from 90.45 Cr in March 2024, while total assets also rose to 123.69 Cr in March 2025. Cash flow from operating acti...

Brooks Laboratories Faces Bearish Outlook Despite Positive Financial Performance

2025-10-28 08:11:12

Brooks Laboratories, a microcap in the Pharmaceuticals & Biotechnology sector, has undergone a recent evaluation adjustment reflecting a bearish technical outlook. Despite strong Q1 FY25-26 financial results, long-term fundamentals reveal challenges, including a stagnant growth rate and difficulties in debt servicing, contributing to a negative annual return.

Brooks Laboratories Forms Death Cross, Signaling Potential Bearish Trend

2025-10-27 18:25:37

Brooks Laboratories has recently encountered a Death Cross, indicating a potential shift in market sentiment. The stock has declined 1.54% today and has underperformed over the past year, with a significant drop compared to the Sensex. Technical indicators suggest ongoing challenges for the company.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

15-Nov-2025 | Source : BSE

Newspaper Publication dated 15th November 2025 of the Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2025.